The Evidence Gap Behind AI Clinical Decision Support

The evidence gap behind AI clinical decision support

AI-driven clinical decision support is now embedded across US hospital systems at a pace that outstrips the clinical evidence validating it, a dynamic Nature Medicine and Clinical Trial Vanguard describe bluntly: adoption is scaling up fast, and the evidence is not keeping pace. For compliance and technology leaders in regulated health systems, this is not an abstract research concern. It is the actual decision in front of you when a vendor asks for sign-off on a new AI-enabled tool.

The FDA has, to its credit, built real infrastructure for this problem. Its framework for Software as a Medical Device includes the 2023 draft guidance on Predetermined Change Control Plans, which lets manufacturers pre-specify how a model may be modified post-authorization without triggering a new submission each time. Fact.MR’s market analysis of high-risk IMDRF Category III and IV software attributes projected 14.6% US CAGR growth partly to this maturing pathway, including lifecycle management, cybersecurity, and predetermined change control expectations. The agency is also showing procedural flexibility on newer generative AI devices, as Mintz’s FDA in Flux newsletter notes regarding two recent generative AI device authorizations. Cadence’s HypertensionOS, a prescription SaMD supporting clinician-supervised titration for Stage 2 hypertension, has joined FDA’s TEMPO program, a live example of the agency working within predefined eligibility and safety checks rather than open-ended autonomy.

That infrastructure is exactly what is missing one step upstream, in clinical trials. Bourne Partners’ research, reported by BioXconomy, found regulatory uncertainty is the primary barrier to AI adoption among trial sponsors and contractors, with limited explicit rules governing how AI can be used in trial design and execution. The contrast is instructive. Where FDA has built a specific pathway, product authorization and even generative AI flexibility follow. Where it has not, adoption stalls despite investor enthusiasm.

What this means for deployment decisions

Do not treat FDA authorization of an AI CDS tool as a proxy for adequate clinical evidence. Authorization confirms the pathway exists and the manufacturer followed it. It does not confirm the underlying evidence base matches your patient population, your care setting, or your risk tolerance. Before onboarding any AI CDS tool, require the vendor’s predetermined change control plan documentation, not just a summary of it, and map your own monitoring obligations against it under your ISO 42001 AI management system, if you have one. If you are procuring AI for trial operations rather than bedside care, assume the regulatory scaffolding is thinner and build your own evidence and audit trail accordingly, since the agency has not yet done that work for you.

The FDA is building the runway. It has not yet built the whole airport. Buyers who confuse the two will be the ones explaining the gap to a regulator later.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that FDA authorization infrastructure exists for deployed devices but not for clinical trial AI use—is coherent and supported, but the piece conflates ‘evidence gap’ (clinical valida
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but some sources could be more robust or directly relevant to the claims they support.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects FDA SaMD frameworks and ISO 42001/AI Act expectations but does not explicitly address MDR/IVDR conformity or EU-specific AI Act risk classification details.
Technical Accuracy	Llama	cleared. The article accurately describes the current state of AI clinical decision support and the regulatory landscape, but some technical details and sources could be scrutinized further for accuracy.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and counters potential vendor hype by distinguishing between FDA authorization and robust clinical evidence, while also highlighting areas where regulatory clarity
Novelty & Non-Duplication	Grok	held. Core thesis, title framing, and evidence-gap claim are lifted nearly intact from the cited Clinical Trial Vanguard wire piece, with the rest a thin synthesis of other recent FDA/SaMD items and no disc
Validation	DeepSeek	cleared. The central claim that AI CDS adoption outpaces clinical evidence is strongly supported by the cited Nature Medicine/Vanguard article and the broader industry analysis of regulatory uncertainty.

Sources cited: 14. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.